Ocugen
Update in progressOCGN (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines. Its pipeline includes OCU400, a retinal gene therapy in Phase 3 for retinitis pigmentosa and Phase 1/2 for Leber congenital amaurosis; OCU410 for dry AMD; OCU410ST for Stargardt disease; OCU200 for diabetic macular edema, retinopathy, and wet AMD; and NeoCart for knee cartilage repair. It also develops OCU500 (COVID-19 vaccine), OCU510 (seasonal flu), and OCU520 (flu plus COVID-19). Collaborations with NIAID and CanSino Biologics. Founded 2013, Malvern, PA.
Company score
- Sentiment
- 0.82
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.61
- Governance
- 0.26
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.24
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.53
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEODr. Shankar Musunuri M.B.A., Ph.D.
- Founded2013
- Employees116
- Websitewww.ocugen.com
Identifiers
- ISINUS67577C1053
- FIGIBBG00194VJB1
- LEI549300JVNUI9CXWJLR09
- CUSIP43358V109
- CIK0001372299